EX-16.1 2 d935959dex161.htm EX-16.1 EX-16.1

Exhibit 16.1

April 18, 2025

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read the statements made by Soleno Therapeutics, Inc. under Item 4.01 of its Form 8-K dated April 18, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Soleno Therapeutics, Inc. contained therein.

Very truly yours,

/s/ Marcum LLP

Marcum LLP